سعر لوسينتيس 10مجم/مل 0.23مل حقن 2024

Lucentis (ranibizumab) 10 mg/ml solution for intravitreal injection, single-use vial containing 0.23 ml (2.3 mg), by Novartis; anti-VEGF treatment for neovascular retinal diseases.

• Neovascular (wet) age-related macular degeneration (AMD)Population: AdultsEuropean Medicines Agency (EMA)
• Visual impairment due to diabetic macular oedema (DME)Population: AdultsEuropean Medicines Agency (EMA)
• Proliferative diabetic retinopathy (PDR)Population: AdultsEuropean Medicines Agency (EMA)

• Mostly injection-related. Very common: intraocular inflammation (vitritis), vitreous detachment, retinal haemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign-body sensation, increased lacrimation, blepharitis, dry eye, ocular hyperaemia, eye pruritus, increased IOP, nasopharyngitis, headache. Most frequent non-ocular reactions: headache, nasopharyngitis and arthralgia. Serious but less frequent: endophthalmitis, blindness, retinal detachment, retinal tear, iatrogenic traumatic cataract.International label, same product · European Medicines Agency (EMA)

• Hypersensitivity to ranibizumab or any excipient; active or suspected ocular or periocular infection; active severe intraocular inflammation.International label, same product · European Medicines Agency (EMA)

• Intravitreal injection-related endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract; transient and sustained intraocular pressure increases (monitor IOP and optic nerve perfusion); potential immunogenicity; do not use concurrently with other anti-VEGF medicines; withhold for BCVA loss ≥30 letters, IOP ≥30 mmHg, retinal break, large subfoveal haemorrhage or intraocular surgery within 28 days; caution with risk factors for retinal pigment epithelial tear; discontinue in rhegmatogenous retinal detachment or stage 3-4 macular hole.International label, same product · European Medicines Agency (EMA)

• Other anti-VEGF medicinal products (systemic or ocular)Should not be administered concurrently with other anti-VEGF medicines; no formal interaction studies were performed.European Medicines Agency (EMA)

• No clinical data on exposed pregnancies; systemic exposure is low but, by its mechanism, ranibizumab must be regarded as potentially teratogenic and embryo-/foetotoxic; do not use in pregnancy unless the benefit outweighs the risk. Women of childbearing potential should use effective contraception; wait at least 3 months after the last dose before conceiving.International label, same product · European Medicines Agency (EMA)
• Based on very limited data ranibizumab may be excreted in human milk at low levels; effect on the breastfed infant unknown; breast-feeding is not recommended during use.International label, same product · European Medicines Agency (EMA)

• Ranibizumab: Binds with high affinity to VEGF-A isoforms (e.g. VEGF110, VEGF121, VEGF165), preventing binding to VEGFR-1 and VEGFR-2 and thereby reducing endothelial proliferation, vascular leakage and neovascularisation (EU SmPC 5.1).